OBJECTIVE: Folic acid fortification has reduced neural tube defect prevalence by 50% to 70%. It is unlikely that fortification levels will be increased to reduce neural tube defect prevalence further. Therefore, it is important to identify other modifiable risk factors. Vitamin B(12) is metabolically related to folate; moreover, previous studies have found low B(12) status in mothers of children affected by neural tube defect. Our objective was to quantify the effect of low B(12) status on neural tube defect risk in a high-prevalence, unfortified population. METHODS: We assessed pregnancy vitamin B(12) status concentrations in blood samples taken at an average of 15 weeks' gestation from 3 independent nested case-control groups of Irish women within population-based cohorts, at a time when vitamin supplementation or food fortification was rare. Group 1 blood samples were from 95 women during a neural tube defect-affected pregnancy and 265 control subjects. Group 2 included blood samples from 107 women who had a previous neural tube defect birth but whose current pregnancy was not affected and 414 control subjects. Group 3 samples were from 76 women during an affected pregnancy and 222 control subjects. RESULTS: Mothers of children affected by neural tube defect had significantly lower B(12) status. In all 3 groups those in the lowest B(12) quartiles, compared with the highest, had between two and threefold higher adjusted odds ratios for being the mother of a child affected by neural tube defect. Pregnancy blood B(12) concentrations of <250 ng/L were associated with the highest risks. CONCLUSIONS: Deficient or inadequate maternal vitamin B(12) status is associated with a significantly increased risk for neural tube defects. We suggest that women have vitamin B(12) levels of >300 ng/L (221 pmol/L) before becoming pregnant. Improving B(12) status beyond this level may afford a further reduction in risk, but this is uncertain.
OBJECTIVE:Folic acid fortification has reduced neural tube defect prevalence by 50% to 70%. It is unlikely that fortification levels will be increased to reduce neural tube defect prevalence further. Therefore, it is important to identify other modifiable risk factors. Vitamin B(12) is metabolically related to folate; moreover, previous studies have found low B(12) status in mothers of children affected by neural tube defect. Our objective was to quantify the effect of low B(12) status on neural tube defect risk in a high-prevalence, unfortified population. METHODS: We assessed pregnancy vitamin B(12) status concentrations in blood samples taken at an average of 15 weeks' gestation from 3 independent nested case-control groups of Irish women within population-based cohorts, at a time when vitamin supplementation or food fortification was rare. Group 1 blood samples were from 95 women during a neural tube defect-affected pregnancy and 265 control subjects. Group 2 included blood samples from 107 women who had a previous neural tube defect birth but whose current pregnancy was not affected and 414 control subjects. Group 3 samples were from 76 women during an affected pregnancy and 222 control subjects. RESULTS: Mothers of children affected by neural tube defect had significantly lower B(12) status. In all 3 groups those in the lowest B(12) quartiles, compared with the highest, had between two and threefold higher adjusted odds ratios for being the mother of a child affected by neural tube defect. Pregnancy blood B(12) concentrations of <250 ng/L were associated with the highest risks. CONCLUSIONS: Deficient or inadequate maternal vitamin B(12) status is associated with a significantly increased risk for neural tube defects. We suggest that women have vitamin B(12) levels of >300 ng/L (221 pmol/L) before becoming pregnant. Improving B(12) status beyond this level may afford a further reduction in risk, but this is uncertain.
Authors: J L Mills; J Tuomilehto; K F Yu; N Colman; W S Blaner; P Koskela; W E Rundle; M Forman; L Toivanen; G G Rhoads Journal: J Pediatr Date: 1992-06 Impact factor: 4.406
Authors: R J Berry; Z Li; J D Erickson; S Li; C A Moore; H Wang; J Mulinare; P Zhao; L Y Wong; J Gindler; S X Hong; A Correa Journal: N Engl J Med Date: 1999-11-11 Impact factor: 91.245
Authors: Joel G Ray; Philip R Wyatt; Miles D Thompson; Marian J Vermeulen; Chris Meier; Pui-Yuen Wong; Sandra A Farrell; David E C Cole Journal: Epidemiology Date: 2007-05 Impact factor: 4.822
Authors: Margaret L Watkins; Sonja A Rasmussen; Margaret A Honein; Lorenzo D Botto; Cynthia A Moore Journal: Pediatrics Date: 2003-05 Impact factor: 7.124
Authors: Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg Journal: JAMA Date: 2007-06-06 Impact factor: 56.272
Authors: M T Steen; A M Boddie; A J Fisher; W Macmahon; D Saxe; K M Sullivan; P P Dembure; L J Elsas Journal: Prenat Diagn Date: 1998-06 Impact factor: 3.050
Authors: Lindsay H Allen; Joshua W Miller; Lisette de Groot; Irwin H Rosenberg; A David Smith; Helga Refsum; Daniel J Raiten Journal: J Nutr Date: 2018-12-01 Impact factor: 4.798
Authors: Jorge Rosenthal; Natalia Largaespada; Lynn B Bailey; Michael Cannon; C J Alverson; Dayrin Ortiz; Gail Pa Kauwell; Joe Sniezek; Ramon Figueroa; Robyn Daly; Peter Allen Journal: J Nutr Date: 2017-04-12 Impact factor: 4.798
Authors: Courtney R Benoit; Abigail E Stanton; Aileen C Tartanian; Andrew R Motzer; David M McGaughey; Stephen R Bond; Lawrence C Brody Journal: J Biol Chem Date: 2018-09-20 Impact factor: 5.157